Market Signal Briefing

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Cardano (ADA) founder Charles Hoskinson has tasked the Midnight development with the responsibility of building the largest private smart contract. Hoskinson’s charge to the team comes after a Cardano developer advocate, Stevan Lohja, confirmed rapid technical growth on Midnight.

Midnight network is growingFor context, Lohja shared that the Midnight Foundation is pushing the team aggressively to ensure the growth of the ecosystem. He mentioned that Midnight’s activity is driving more usage on Cardano. More importantly, though, Lohja revealed some numbers on the progress made by the team.

He stated that the smart contract deployments on Midnight are up 44.6% in the third quarter (Q3). Meanwhile, the new contracts being created are up 45.4% in the weekly average deployments. This shows that Midnight is recording positive developer growth.

Despite that, Hoskinson is charging the team to intensify efforts and become more "aggressive" than they already are pushing. He wants Midnight to become the world’s leading privacy-oriented smart contract platform by the end of 2026.

This is a clear and bold goal. However, the challenge is that it is aiming to outperform all other privacy chains, such as Secret Network. Others are Oasis Network with approximately 13.6% of the market share and Aleph Zero, holding 6.1% of the market share.

Hoskinson is aware that these platforms will not just sit idle and watch Midnight take over, hence the charge to the team, "Every week more aggressive."

The Cardano privacy pursuit was first open to handpicked developers in late 2023 to test-run it. Eventually, in February 2024, it was opened to the public, which allows developers to experiment and innovate, thereby contributing to growing the space.

Can Midnight overcome its technical challenges?According to Charles Hoskinson, the Midnight network, in collaboration with Brave Wallet, could transform the lives of millions. Starting with Brave Wallet’s 84 million users, they would enjoy advanced cryptographic protection, as Midnight serves as a privacy layer in the internet space.

He believes that Midnight could change the lives of billions of users by improving security and privacy for web users.

The Midnight development has not been without challenges. In August 2025, Bitcoin claims on the Ledger device produced error messages such as "No eligible addresses found or recognized."

The team had to quickly resolve the problem to retain users’ confidence in the platform. With a 2026 timeline now set, the broader crypto space will be looking forward to seeing how efficient the Midnight network could become.

XRP has rebounded in the past 24 hours after another violent Friday.

It’s safe to say that XRP, alongside most of the cryptocurrency market, has been in a dire state for the past few weeks, which was exacerbated on October 10 with a painful crash that was almost mimicked a week later.

Ripple’s native token, though, has recovered some ground following the low charted yesterday, and now sits close to $2.40 after a 4% daily increase.

Data shared by Santiment shows that the long-term trends for the token remain positive as the number of mid- to large stakeholders “continues to grow.” More precisely, the wallets containing at least 10,000 tokens have hit a new all-time high of 317.5K, the analytics resource said. Additionally, the chart shows a consistent increase for nearly a year after a brief slip in late 2024.

📊 XRP’s price has rebounded back a modest +5.3% since its bottom 12 hours ago. A good long-term sign is the amount of mid to large stakeholders continues to grow. There are now an all-time high ~317.5K wallets with at least 10K $XRP.

🔗 Chart link: https://t.co/iI8L53Ue7a pic.twitter.com/qOom9t876s

— Santiment (@santimentfeed) October 17, 2025

Cobb presented even more positive news for the XRP Army, this time in terms of overall development of the network and engagement of its meme coin ecosystem. The commentator noted that Ripple-based meme tokens have exploded in the past day.

Why are XRP memes suddenly sending???? pic.twitter.com/VM6IvvY7ZT

— Cobb (@Cobb_XRPL) October 18, 2025

Later on, Cobb explained that a whale had jumped into the XRP meme landscape by splashing $1 million into blue-chip tokens.

You may also like:

Ripple (XRP) Pauses After Chaos: Is Wave 5 Still Coming or a New Bull Trend Emerging?

Ripple Labs Reportedly Leading $1B Fundraise for XRP Treasury 

XRP Price Plunged 20% Amid Significant Whale Inflows to Binance

In terms of price action and performance, CRYPTOWZRD said the asset closed indecisively against the greenback, although the XRP/BTC pair “needs to push more bullish from here to help XRP.” The analyst said the expectations for the weekend should remain “rational,” and hinted that more volatility is expected at the start of the new business week.

Story HighlightsThe live price of the RNDR token is  $ 2.51659805.Render token with a potential high could reach $12.205 in 2025.With a potential high the RNDR price could hit $85.11 by 2030.Render began as a way to turn idle GPUs into a global 3D rendering powerhouse, rewarding providers with RENDER tokens. It has built trust through real-world use, a known team, and consistent utility across multiple crypto cycles.

Now, Render is stepping beyond its roots in 3D rendering. Its US-based GPU node trial for AI inferencing, launched in July 2025, is showing early success with 80% utilization. Moreover, Render Network is advancing decentralized AI with U.S. trials by onboarding node operators using NVIDIA’s RTX 5090.

Do you want to know if RNDR is a good choice for the future? Look no further as we unfold the most realistic RNDR price prediction for 2025 and the years to come!

Render Price TodayCryptocurrencyRenderTokenRENDERPrice$2.5166 2.63% Market Cap$ 1,305,069,034.9124h Volume$ 45,301,370.3920Circulating Supply518,584,616.1641Total Supply533,344,789.4441All-Time High$ 13.5961 on 17 March 2024All-Time Low$ 0.0368 on 16 June 2020*The statistics are from press time.

Render Price ChartTechnical AnalysisRender (RNDR) is trading around $2.491, struggling below the 20-day SMA at $3.079 after a recent decline. Technicals indicate:

Key Support: $2.150 (lower Bollinger Band), $2.451 (recent low)Resistance: $3.079 (20-day SMA), $4.007 (upper Bollinger Band)Indicators: RSI at 36.05 shows bearish momentum, nearing oversold territory.RNDR Short-Term Price PreditionRender Token Price Prediction 2025With real adoption, a credible team, and deep liquidity, Render stands out in the crowded AI crypto space. Optimism dominates sentiment, and if partnerships and usage expand globally, RNDR could see its value rise even further. Successively, the price could rise to a maximum of $12.205 in 2025.

However, if it confronts tougher opposition from evolving rivals, the value could fall to $3.35. The equilibrium in the bullish and bearish targets could land the average price at $7.47.

YearPotential LowPotential AveragePotential High2025$3.35$7.47$12.205Also Check out: Helium Price Prediction 2025, 2026 – 2030!

Render Token Mid-Term Price PredictionYearPotential Low ($)Potential Average ($)Potential High ($)20265.6011.20516.8120278.4016.8125.22Render Token Price Prediction 2026According to our analysts, the RNDR Token price prediction for the year 2026 could range between $5.60 and $16.81, and the average price of the Render Token could be around $11.205.

Render Price Forecast 2027According to our analysts, the Render price for the year 2027 could range between $8.40 to $25.22, and the average price of RNDR Token could be around $16.81.

Render Long-Term Price PredictionYearPotential Low ($)Potential Average ($)Potential High ($)202812.6025.2237.83202918.9037.8356.74203028.3556.7485.11RNDR Crypto Price Forecast 2028According to our analysts, the RNDR crypto prediction for the year 2028 could range between $12.60 and $37.83, and the average Render Token price could be around $25.22.

Render Token Price Prediction 2029According to our analysts, the Render Token forecast for the year 2029 could range between $18.90 to $56.74, and the average RNDR coin price could be around $37.83.

RNDR Token Price Projection 2030According to our analysts, RNDR Token predictions for the year 2030 could range between $28.35 to $85.11, and the average Render price could be around $56.74.

Market AnalysisFirm Name202520262030Wallet Investor$2.012$1.630–priceprediction.net$10.39$15.09$62.83DigitalCoinPrice$16.71$22.83$49.91*The targets mentioned above are the average targets set by the respective firms.

CoinPedia’s RNDR Price PredictionCoinPedia’s price estimate for the Render Token (RNDR) indicates that the token has a fantastic environment for gaming and videos. In light of its performance over the prior year.

Render Token may experience big growth by the end of this year and surpass the $10 mark with a possible high of $12.205. In more detail, we predict that the price of RNDR will vary between $3.735 and $7.47.

YearPotential LowPotential AveragePotential High2025$3.35$7.47$12.205FAQsHow many Render Token coins are there?

With a current circulating supply of around 518.12 million coins. Notably, it has a maximum supply of 644.16 million RENDER tokens.

Is Render a good investment?

The coin has solid fundamentals and great rendering capabilities, which make it a good long-term hold.

What will the maximum price of Render Token be by the end of 2025?

The RNDR price can potentially rise as high as $12.205 in 2025.

Where to buy a Render Token?

All major exchanges like Coinbase, Binance, etc have listed RNDR on their exchanges for trading.

What will the Render price be in 2030?

The Render Token is expected to reach a maximum value of over $56.74 by 2030.

What is a Render Token?

The Render Token supports blockchain technology that can be used to revitalize rendering options for video game illustrations.

Is Render an AI coin?

Yes, Render token is considered to be the most successful Artificial Intelligence (AI) token.

How can I buy RNDR?

The Render token is listed on all major and minor crypto exchanges, thus making it easily available for one to buy and sell.

What is the price of Render?

At the time of writing, the price of 1 RNDR was  $ 2.51659805.

ProsThe protocol employs Blockchain.Com information technology to present a competitive and superior substitute.Render Token users can work with complicated files that are difficult to process locally.It uses the immutability of blockchain technology to protect creators’ rights.ConsOne of the disadvantages of Render Token is that anyone can easily share unused GPU power.Since GPUs are idle, new customers are forced to purchase brand-new GPUs.It can be time-consuming for people with high-end rendering requirements. Disclaimer and Risk WarningThe price predictions in this article are based on the author's personal analysis and opinions. CoinPedia does not endorse or guarantee these views. Investors should conduct independent research before making any financial decisions.

Dogecoin's been getting absolutely hammered this week, dropping over 27% in just seven days. On Friday alone it fell another 7% to land at $0.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CRWV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

3M logo is seen at the International Defence Industry Exhibition in Kielce, Poland, on September 2, 2025. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

NurPhoto via Getty Images

3M (NYSE: MMM) is set to release its earnings on Tuesday, October 21, 2025. This report holds significant importance for traders, especially those who utilize event-driven strategies.

In the past five years, 3M’s stock has shown a balanced response to earnings announcements, with an even division of positive and negative one-day returns after the results. In 50% of cases, the stock recorded a positive one-day return, averaging 4.8%. On the other hand, in the remaining 50% of cases, it faced a negative one-day return with an average of -2.8%. This historical trend indicates a considerable level of volatility and an absence of a consistent upward or downward trend following earnings.

For the upcoming third quarter of 2025, consensus predictions expect earnings of $2.07 per share on revenue of $6.26 billion. This contrasts with the earnings per share of $2.14 from the same quarter last year, even though current sales are projected to surpass the previous year’s $6.07 billion.

While the actual financial results and their comparison to consensus and expectations will significantly shape the stock’s immediate response, grasping these historical patterns can offer crucial insights for event-driven traders. There are two main strategies to contemplate:

Pre-Earnings Positioning: Based on the historical probabilities, a trader might opt to take a position prior to the earnings release, anticipating a move (either upwards or downwards) and managing the related risk considering the 50/50 distribution in past results.Post-Earnings Positioning: Alternatively, a trader might decide to wait for the earnings release, examine the immediate market reaction and the connection between short-term and medium-term returns, and subsequently position themselves accordingly after the announcement.From a fundamental standpoint, 3M currently possesses a market capitalization of around $81 billion. Over the past twelve months, the company generated $25 billion in revenue. It exhibited operational profitability with $4.8 billion in operating profits and a net income of $3.9 billion.

That said, if you are seeking an upside with less volatility than holding an individual stock, consider the High Quality Portfolio. It has significantly outperformed its benchmark—a combination of the S&P 500, Russell, and S&P MidCap indexes—and has achieved returns exceeding 105% since its inception. Why is that? As a group, HQ Portfolio stocks provided superior returns with reduced risk compared to the benchmark index; less of a roller-coaster experience, as shown in HQ Portfolio performance metrics.

View earnings reaction history of all stocks

3M’s Historical Odds Of Positive Post-Earnings ReturnA few observations regarding one-day (1D) post-earnings returns:

There are 20 earnings data points documented over the past five years, with 10 positive and 10 negative one-day (1D) returns recorded. In summary, positive 1D returns occurred approximately 50% of the time.Interestingly, this percentage rises to 58% when we analyze data from the last 3 years instead of 5.Median of the 10 positive returns = 4.8%, and median of the 10 negative returns = -2.8%Additional information for observed 5-Day (5D) and 21-Day (21D) returns following earnings are presented along with the statistics in the table below.

MMM 1D, 5D, and 21D Post Earnings Return

Trefis

Correlation Between 1D, 5D, and 21D Historical ReturnsA relatively less risky approach (though not effective if the correlation is weak) is to comprehend the correlation between short-term and medium-term returns after earnings, identify a pair that displays the highest correlation, and perform the suitable trade. For instance, if 1D and 5D exhibit the strongest correlation, a trader can position themselves “long” for the following 5 days if the 1D post-earnings return is positive. Below is some correlation data derived from a 5-year and a 3-year (more recent) history. Note that the correlation 1D_5D relates to the correlation between 1D post-earnings returns and subsequent 5D returns.

Correlation Between 1D, 5D, and 21D Historical Returns

Trefis

Investing in a single stock without thorough analysis can be risky. Consider the Trefis Reinforced Value (RV) Portfolio, which has outperformed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to deliver robust returns for investors. Why is that? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks provided an adaptive way to make the most of improving market conditions while minimizing losses during downturns, as elaborated in RV Portfolio performance metrics.

HDFC Bank Ltd., India's largest private sector lender, reported a stronger-than-expected profit for the September quarter, supported by steady loan growth and improving asset quality, even as pressure on margins persisted.

HomeMarketsCommodities CornerCommodities CornerCentral banks view gold as a ‘key, liquid component of their reserves’Published: Oct. 18, 2025 at 7:00 a.m. ET

Germany’s central bank, the Deutsche Bundesbank, holds the world’s second-largest gold reserves, behind the U.S. Photo: Deutsche Bundesbank/Agence France-Presse/Getty ImageGold prices at record highs sounds like a broken record, but central banks have continued to buy more than they’re selling, even with prices for the precious metal at their highest levels ever.

“Central banks continue to be consistent and strategic buyers of gold, even at record prices, because of the role it plays in strengthening their reserve portfolios,” Joe Cavatoni, senior market strategist at the World Gold Council, said in comments sent to MarketWatch Friday.

SummaryThis article provides a top-down analysis of the industrial sector, focusing on value and quality metrics.Transportation remains slightly undervalued, while aerospace/defense is the most overvalued subsector based on historical averages.FIDU and XLI are nearly equivalent for long-term investors, but XLI offers higher liquidity and better recent performance.Nine stocks that are cheaper than their peers in October.Quantitative Risk & Value members get exclusive access to our real-world portfolio. See all our investments here »Monty Rakusen/DigitalVision via Getty Images

This monthly article series reports subsector metrics, aiming at a top-down analysis of the industrials sector. It may also help analyze sector ETFs such as Industrial Select Sector SPDR ETF (XLI) and Fidelity MSCI

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in TSM over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The world’s largest investment management firm, BlackRock (NYSE: BLK), has disclosed a 5.4% ownership stake in biopharmaceutical company Sellas Life Sciences Group (NASDAQ: SLS).

Specifically, the stake amounts to 5,686,886 shares, giving the investment giant voting control in the company, according to a Schedule 13G filing with the U.S. Securities Exchange Commission.

BlackRock SLS stock transaction. Source: SEC
Notably, BlackRock’s endorsement comes at a crucial time as SLS stock has shown strong bullish momentum in recent sessions. In after-hours trading on Friday, the stock rallied 38%, having closed the day’s session at $2.14, marking a 100% gain year to date.

SLS YTD stock price chart. Source: Google Finance
SLS stock fundamentals 
At the same time, the firm’s fundamentals appear to support potential sustained growth. Sellas Life Sciences, a late-stage biotechnology firm, has recently demonstrated meaningful clinical progress across its pipeline.

The company’s lead candidate, galinpepimut-S (GPS), is currently in a Phase 3 trial known as REGAL, targeting acute myeloid leukemia (AML). The independent data-monitoring committee overseeing the study confirmed that the trial could proceed without modification after a positive interim safety review. 

Median survival among patients has reportedly exceeded 13.5 months, more than double the historical average for standard treatments. The final data readout is expected by the end of 2025.

Sellas’s second key notable program, SLS009 (tambiciclib), a selective CDK9 inhibitor also targeting AML, has produced encouraging Phase 2 results. 

To this end, part of Friday’s rally came after reports that SLS009 showed strong preclinical results in T-cell prolymphocytic leukemia, improving survival and reducing tumor burden both alone and in combination with venetoclax.

The U.S. Food and Drug Administration (FDA) has already granted Sellas Fast Track and Orphan Drug designations for both programs, with guidance to initiate a first-line AML trial for SLS009 in early 2026.

Overall, BlackRock’s disclosure suggests growing institutional confidence in Sellas’s long-term potential despite the inherent risks of biotech investing. 

For investors, future valuation will likely hinge on the outcome of the REGAL trial, which could prove transformative if final data confirm the early survival benefit.

Featured image via Shutterstock

SummaryNeurocrine Biosciences is rated BUY, driven by strong INGREZZA sales, Prenepsi growth, and a promising late-stage neuropsychiatry pipeline.NBIX's Q2 2025 revenue reached $682 million, with INGREZZA contributing 91% and Prenepsi expanding its rare-disease market presence.Robust cash reserves of $1.8 billion and disciplined expense management position NBIX to self-fund pipeline innovation and future product launches.Key risks include revenue concentration in INGREZZA, pricing pressures, and clinical pipeline uncertainty, but NBIX's competitive edge and growth prospects remain compelling. J Studios/DigitalVision via Getty Images

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock has had a stellar six-month performance with double-digit gains, recovering from 52-week lows recorded in April 2025. However, the past month has been slowish, with marginal losses of below one percent. That said, the

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

SummaryPayPal Holdings Inc. is undervalued, with a fair value estimate of $143/share versus its current price near $67, offering 114% upside.PYPL's strengths include robust free cash flow, omnichannel presence, trusted brand, and aggressive share buybacks, supporting long-term shareholder value.Key risks for PYPL are rising competition, increasing debt, regulatory fines, and operational vulnerabilities, though its innovation and scale remain advantages.Despite operational and regulatory risks, PYPL presents a compelling long-term investment opportunity in digital payments, trading at a significant discount to intrinsic value. hapabapa/iStock Editorial via Getty Images

Investment Thesis PayPal Holdings Inc. (NASDAQ:PYPL) presents a highly attractive investment opportunity. Its current P/E ratio of slightly under 15 underscores how the market continues to undervalue its long-term cash flow potential. Additionally, growth in net

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer
The information provided by Moods Investment Research is for general informational and educational purposes only. It is not intended as, and does not constitute, financial, investment, tax, legal, or other advice. The content is not a solicitation or recommendation to buy, sell, or hold any securities or investment strategies.
All opinions expressed are based on current analysis and are subject to change without notice. While we strive for accuracy, Moods Investment Research makes no representation or warranty as to the completeness, accuracy, or reliability of any information provided. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Moods Investment Research and its founders, directors, or affiliates are not liable for any losses or damages arising from any reliance on the information provided.
The views expressed in this article are those of the author(s) and do not constitute investment advice. The author holds no position in PayPal. However, the author(s), including any editors or contributors (collectively referred to as “Moods and directors”), may or may not hold positions in other securities mentioned. Any such holdings are subject to change without notice.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Tesla (TSLA) reports third quarter earnings results on Wednesday, Oct. 22, with Wall Street expecting $26.27 billion in revenue and $0.53 in adjusted earnings per share (EPS). Investors anticipate fresh commentary from Tesla CEO Elon Musk, as well as insights into the electric vehicle (EV) maker's China sales and cheaper new models.

Traffic drives in view of a Boeing Co. production plant, where images of jets decorate the hangar doors on April 23, 2021, in Everett, Wash. Credit: AP Photo/Elaine Thompson, File

The Federal Aviation Administration said Friday it will allow Boeing to produce more 737 Max airplanes by increasing the monthly limit that it imposed after a door plug blew off an Alaska Airlines jet that the company built.

Boeing can now produce 42 Max jets per month, up from 38, after safety inspectors conducted extensive reviews of the aerospace company's manufacturing lines to ensure an increase in production can be done safely, the FAA said.

The agency had set a cap on production shortly after the terrifying January 2024 incident involving the Alaska Airlines 737 Max jet. In practice, though, the production rate fell well below the ceiling last year as the company contended with investigations and a machinists' strike that idled factories for almost eight weeks. But Boeing said over the summer that it had reached the monthly cap in the second quarter and would eventually seek the FAA's permission to start producing more of the planes.

A spokesperson for Boeing said Friday that the company followed a "disciplined process" to make sure it was ready to safely increase production, using safety guidelines and performance goals that it set with the FAA.

"We appreciate the work by our team, our suppliers and the FAA to ensure we are prepared to increase production with safety and quality at the forefront," Boeing said in a statement.

The FAA also said Friday this won't change the way it oversees Boeing production processes and its efforts to strengthen the company's safety culture, adding that FAA inspectors at Boeing plants have continued to work through the federal government shutdown that began Oct. 1.

Just last month, the FAA also restored Boeing's ability to perform final safety inspections on 737 Max jetliners and certify them for flight. Boeing hadn't been allowed to do that for more than six years, after two crashes of the then-new model killed 346 people. The FAA took full control over 737 Max approvals in 2019, after the second of the two crashes that were later blamed on a new software system Boeing developed for the aircraft.

Earlier this year, Boeing CEO Kelly Ortberg faced questions from a Senate committee about the production rate of the 737 Max, with lawmakers seeking reassurance from Ortberg that the company was prioritizing quality and safety over meeting production targets for profit.

"Just to be very clear, we won't ramp up production if the performance isn't indicating a stable production system," Ortberg said at the April hearing. "We will continue to work on getting to a stable system."

The incident involving the Alaska Airlines flight that prompted the production cap on Max jets was among a series of alleged safety violations by Boeing between September 2023 and February 2024 that led to the FAA seeking $3.1 million in fines from the company.

© 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation:
FAA allows Boeing to increase 737 Max production nearly two years after door plug flew off plane (2025, October 18)
retrieved 18 October 2025
from https://techxplore.com/news/2025-10-faa-boeing-max-production-years.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of FDUS, BXSL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryPizza Pizza Royalty Corp. benefits from its low-cost, low-capital, high-margin business model as its financials remain well-positioned.Its prudent management of the royalty pool ensures increasing royalty income per store, margin expansion, and robust cash flow to ensure sustained expansion and dividend payouts.Its valuation stays cheap with decent dividend yields, justifying some upside potential.Technicals have weakened recently, but the selloff has opened new entry points amid rebounding buying volume.ArtistGNDphotography/E+ via Getty Images

Three months after my initial analysis of Pizza Pizza Royalty Corp. (OTCPK:PZRIF) (TSX:PZA:CA), we saw more developments that continued to support my buy rating. Its strategic business model and sound fundamentals ensure its

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PZA:CA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Nvidia (NASDAQ: NVDA) CEO Jensen Huang has sold a substantial amount of company stock, continuing his renewed selling spree amid the equity’s rally.

Filings indicate that over the past three weeks, Huang offloaded more than $250 million worth of NVDA shares under a pre-arranged Rule 10b5-1 trading plan adopted on March 20, 2025.

Between September 24 and October 15, 2025, Huang executed five sales of 225,000 Nvidia shares each. For instance, on October 15, he sold shares at an average price of $183.73, generating $41.3 million, and on October 10, another batch at $190.61 per share for $42.9 million.

NVDA CEO insider stock sales. Source: Barchart
This fits a broader six-month trend in which Huang sold around 5.5 million shares. Experts note such sales are typical for executives receiving RSUs that vest over time.

Despite significant insider selling, analysts see little impact on Nvidia’s outlook. Its 2024 share buyback, which cut the share count by 0.52%, and $11 billion in net cash helped offset dilution, while institutional investors added $70 billion in holdings in Q1 2025. Notably, significant insider sales tend to trigger caution among investors leading to bearish sentiments. 

Analysts bullish on Nvidia stock price 
Recent insider selling has not shaken market optimism, as Nvidia continues to lead the rapidly growing AI chip market. Wall Street remains bullish, with analysts seeing the semiconductor as central to the AI revolution with potential for accelerated stock rally. 

Despite the wave of insider selling, estimates from 38 analysts tracked by TipRanks set the average 12-month price target for Nvidia at $224.69, implying a 22.63% upside from the last closing price of $183.22. 

NVDA stock 12-month stock price chart. Source: TipRanks
The most optimistic forecast values the stock at $320.00, while the lowest estimate stands at $155.

Featured image via Shutterstock

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma.

Media Release

COPENHAGEN, Denmark; October 18, 2025

Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expressionA Phase 3 trial in endometrial cancer is underwayU.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer
Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR), in heavily pretreated patients with advanced endometrial cancer (EC) who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor. Additionally, at a median study follow-up of one year, 63.6% of responders (including CRs) in the 100 mg/m² cohort maintained their responses and remain on treatment. The responses were observed regardless of FRα expression levels. The updated results were presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.

Continued evaluation of single-agent Rina-S 100 mg/m2 in patients with advanced EC is ongoing in the Phase 2 RAINFOL-01 trial (NCT05579366) and the Phase 3 RAINFOL-03 trial (NCT07166094).

“Women with advanced endometrial cancer are often facing a difficult path, while doctors are confronted with not having enough treatment options,” said Noelle Cloven, M.D., Texas Oncology Fort Worth, Sarah Cannon Research Institute, and study investigator. “That’s why these data signals with Rina-S in the updated Phase 1/2 RAINFOL-01 data are encouraging – they point to the possibility of providing more choices for patients in the future.”

The B2 cohort of the Phase 1/2 RAINFOL-01 study (NCT05579366) is a dose expansion cohort evaluating the efficacy and safety of Rina-S in patients with advanced or recurrent endometrial cancer. In the study, 64 patients with heavily pretreated advanced or recurrent endometrial cancer whose disease had progressed on or after an anti-PD-(L)1 and platinum-based chemotherapy were enrolled and treated with Rina-S. Patients were administered either 100 mg/m2 (n=22) (selected dose for Phase 3 clinical trial) or 120 mg/m2 (n=42) of Rina-S. In the 100 mg/m2 cohort, the confirmed ORR was 50.0%, including two CRs. Anti-tumor activity was also observed in patients treated with Rina-S 120 mg/m2 Q3W, which resulted in 44.1% confirmed ORR and one CR. Study participants were previously treated with a median of three lines of therapy (range 1-8). Earlier results from this cohort were previously presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Common treatment emergent adverse events (TEAEs; all grades) consisted primarily of cytopenias and low-grade gastrointestinal (GI) events. To date, there have been no signals of ocular toxicities, neuropathy, or interstitial lung disease (ILD) observed in Rina-S clinical trials consistent with prior reports. Serious TEAEs (Grade 3 or higher), occurred in 36.4% and 52.4% of patients treated with Rina-S 100 mg/m2 and 120 mg/m2, respectively. Hematologic adverse events did not require significant dose reduction and were associated with low rates of treatment discontinuation.

“With this updated data, we are seeing additional momentum behind the possibilities of Rina-S,” said Tahi Ahmadi, M.D., Executive Vice President and Chief Medical Officer, Head of Experimental Medicines at Genmab. “As a wholly owned, novel antibody-drug conjugate, Rina-S reflects Genmab’s vision to accelerate our innovative, late-stage pipeline that has the potential to redefine possibilities for patients with certain gynecologic cancers.”

Rina-S is advancing through late-stage development supported by a growing portfolio of clinical trials, including the ongoing Phase 1/2 RAINFOL-01 trial (NCT05579366), the Phase 3 RAINFOL-03 trial (NCT07166094) in patients with endometrial cancer now underway and the Phase 3 RAINFOL-02 trial (NCT06619236) in patients with platinum resistant ovarian cancer (PROC). The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy Designation (BTD) to Rina-S for the treatment of adult patients with recurrent or progressive EC who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy.

About the RAINFOLTM -01 Trial
RAINFOL™-01 (NCT05579366) is an open-label, multicenter Phase 1/2 study, designed to evaluate the safety and efficacy of rinatabart sesutecan (Rina-S) Q3W at various doses in solid tumors that are known to express FRα. The study consists of multiple parts including Part A dose escalation; Part B tumor-specific monotherapy dose-expansion cohorts; Part C platinum-resistant ovarian cancer (PROC) cohort; Part D combination therapy cohorts; Part F a monotherapy endometrial cancer (EC) cohort.

About Endometrial Cancer
Endometrial cancer (EC) starts in the lining of the uterus, known as the endometriumi and ranks as the second most prevalent gynecologic cancer globally, with increasing incidence and mortality ratesii,iii. Patients with advanced or recurrent EC have a relatively poor prognosis and treatment options are limited for those patients who have progressed following treatment with chemotherapy and immune checkpoint inhibitor. FRα is overexpressed on multiple tumors, including EC, making it a promising therapeutic target. Anti-tumor activity with Rina-S was observed across a broad range of FRα expression, and there are currently no approved FRα-directed therapies approved for the treatment of endometrial cancer.

About Rinatabart Sesutecan (Rina-S; GEN1184)
Rinatabart sesutecan (Rina-S; GEN1184) is an investigational ADC. It is composed of a novel human monoclonal antibody directed at folate receptor α (FRα), a novel hydrophilic protease-cleavable linker, and exatecan, a topoisomerase I inhibitor payload. The clinical trial program for Rina-S continues to expand including ovarian, endometrial and other cancers of unmet need.

The safety and efficacy of rinatabart sesutecan has not been established. Please visit www.clinicaltrials.gov for more information.

About Genmab 
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. 

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:        
David Freundel, Senior Director, Global Communications & Corporate Affairs
T: +1 609 613 0504; E: [email protected]

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: [email protected]

This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect®, KYSO® and RAINFOL™; Rina-S is a trademark of ProfoundBio, US, Co. and Genmab (Suzhou) Co., Ltd.

i Mayo Clinic. Endometrial Cancer. https://www.mayoclinic.org/diseases-conditions/endometrial-cancer/symptoms-causes/syc-20352461.
ii Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: Cancer today (version 1.1). International Agency
for Research on Cancer. 05/28/2024 (https://gco.iarc.who.int/today).
iii Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021;31(1):12-39. (In eng). DOI: 10.1136/ijgc-2020-002230.

Media Release no. i18
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

18102025_i18_RINASESMOEC

Analyst’s Disclosure:I/we have a beneficial long position in the shares of NSRGY, NSRGF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital for potential violations of the federal securities laws.

If you invested in Jefferies or Point Bonita, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action.

Why are Jefferies and Point Bonita being Investigated?

Jefferies is an investment banking and capital markets firm. Its trade finance arm is named Point Bonita Capital. Jefferies and Point Bonita were two of the closest banking and financing partners of First Brands Group, LLC, an auto parts supplier which collapsed into bankruptcy in September 2025.

On October 8, 2025, Jefferies announced that it and Point Bonita had approximately $715 million in exposure to First Brands’ receivables, which represents roughly 25% of Point Bonita’s trade finance portfolio. On this news, the price of Jefferies stock fell $4.66 per share, or about 8%, from $59.10 per share on October 7, 2025, to $54.44 per share on October 8, 2025. Investors are reportedly currently seeking redemptions from Point Bonita as well.

BFA is currently investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors in connection with this significant exposure to First Brands.

Click here for more information: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action.

What Can You Do?

If you invested in Jefferies or Point Bonita you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Attorney advertising. Past results do not guarantee future outcomes.

HANetf co-CEO Hector McNeil spoke to Proactive about rising investor demand for gold and defense ETFs amid global geopolitical tensions.

He outlined the performance of HANetf's gold-related products and defense-themed funds, and discussed how ETFs are helping investors hedge against volatility and currency risk.

Here, we taka a closer look at what was said.

Proactive: Hector, very good to speak with you again. It's been a very active time geopolitically over the past couple of months. And we've seen that reflected both in defence stocks but also in the gold price with the gold price topping $4,000 an ounce.

Tell us about that, because you give exposure to gold both through your Gold Mining ETF as well as Physical Gold ETC.

Hector McNeil: Yes, funny enough, I don't know if I ever told you, Stephen, but my previous company — the first ETF I worked at was ETF Securities and we were well known for inventing the first gold ETF in the world. And I actually said it on a call with a company today that, when we issued that gold ETF back in 2003, gold was $318 an ounce.

So, it just shows you how far the world’s gone since then. I think, actually, ETFs have a lot to answer for, for the rise in demand, because ultimately, they make it very straightforward for people to put gold in their portfolios. Rather than you put it under the bed or in the safe, dig a hole in the ground or whatever, you can safely go and buy your ounce of gold and buy it through a gold ETF.

That's where people have got 5 to 8% of their portfolio in gold now — and that’s what I pretty well recommend people to do anyway. It was very hard to do that before. So, yeah, we have both the physical gold side with the Royal Mint.

We've just got a smidgen under £2 billion in RMAU, which is our showcase gold ETC with the Royal Mint. That’s just under £1.65 billion, and then we created currency-hedged versions earlier this year. They're nearly £300 million now. We've done Swiss franc hedged, euro hedged, and GBP hedged.

So, obviously with Trump devaluing the dollar so aggressively, those are great trades to put on. And then, as you've quite mentioned, we do have a Gold Miners ETF, which had been pretty dormant for a long time in terms of inflows. Then it’s tripled in size, it's up to £65 million now, nearly £70 million.

And it's tripling in the last three or four weeks. I think people see gold miners as a geared play to the gold price. So if you want a leveraged play to the gold price, the gold miners are the place to go. What’s really nice about the Gold Mining ETF (ESGO) as well, it has an ESG screen.

We do screen out companies that we feel are not meeting that high standard. And obviously, in gold companies, there can be a lot of toxicity in mining. That’s where Physical Gold ETC (RMAU) differentiates, because it uses recycled gold, which is 98% less carbon intensive than mined gold because of the toxicity and the logistics involved in moving it around.

Then you've got the other side of the story with ESGO, which is the gold miners. So we’re very happy with both of those products. We feel we've got a very curated offering in that space — whether it’s physical gold, whether it's miners, or whether it’s currency hedged. There are five products there that are very interesting for people to use.

Proactive: So while the gold price has clearly benefited from geopolitical tensions and given its safe haven status, we've also seen the defence stocks doing very well. And due to those tensions, you now have three defence ETFs. So you've got your Global Defence, European Defence, and also the newest addition to the family, your Indo-Pacific Defence ETC. How has that done?

Hector McNeil: Yeah. The global defence one is NATO-focused, which screens just for NATO companies. That's unique. NATO's a defensive alliance, and we think it's really important to have that sort of screen — because you don't want to be putting money in companies that are looking to invade everybody.

Having the NATO screen gives an official capital markets way to invest and support those companies as well. We all know the threats we have with the likes of Russia, North Korea, and China. So from that perspective, it’s a great product.

Then we have ARMY, which is the European product — that's a couple of hundred million. So we're getting almost £3.5 billion now in defence products.

Return-wise, the Gold Mining ETF (ESGO) has had a 130% return this year, which is just insane. It shows the geopolitical impact on gold.

Then, as you mentioned, our newest product is Indo-Pacific x China — that includes countries like Japan, Australia, Korea, India, etc. These are, to some extent, the extension of NATO for that region. It obviously buttresses against the geopolitical dominance of China and areas like North Korea.

Certainly, the performance has been insane for some of those countries. I think some Indian stocks are seeing 500% returns over that time. You probably saw over the weekend that Pakistan had a border skirmish with the Taliban, where over 100 soldiers were killed between the two countries.

In that Indo-Pacific region, we are one geopolitical event away from that being probably a couple of billion as well. I somewhat think if I’d been around when the India-Pakistan war had been in place, then it would have seen a big insight from there.

But QUAD is a very exciting ETF and rounds out our defence offering. Funnily enough, we've just added to our tech megatrend product, ITEK, which has eight megatrends, including cloud, social media, and transport. We just included AI, quantum computing, and defence tech in that basket as well.

So you get those eight megatrends all in one go. We think by adding in defence, it's updating that index to represent what's going on. We've got four products in that space today.

We think with gold and defence, you're pretty well hedged against dollar devaluation and geopolitical events, which seem to be the order of the day at the moment.

Proactive: It looks like that may continue to be the case for quite some time. Hector, as always, thank you very much for your time.

With over four years of experience in covering and tracking the financial markets, Sneha Agrawal is a dedicated Crypto Journalist and Editor with passion for researching and writing the crypto pieces. She is currently leading the Block of Fame, here at CoinGape. She likes to keep track of political, legal and financial happenings all around the world - without which she deems her day incomplete. Apart from her Journalistic endeavours, she is a solo traveler, museum goer, and a keen reader of books.

XRP Whale and Mid-Tier Wallets Hit All-Time High as Accumulation StrengthensAccording to leading on-chain analytics platform Santiment, wallets holding 10,000 or more XRP have reached an all-time high of over 317,500 addresses, signaling intensified accumulation among whales and mid-tier investors. 

Source: SantimentThis milestone underscores growing confidence in XRP’s long-term outlook, even as short-term market volatility persists.

The data show that both whales and mid-tier investors are aggressively accumulating XRP despite recent price swings, a clear sign of growing confidence in its long-term potential. 

Therefore, this steady accumulation often precedes major market moves, suggesting informed investors are positioning early for a potential breakout.

XRP’s price has rebounded by approximately 5.3% in the past 12 hours after finding a local bottom, highlighting renewed buying activity at lower levels. This modest but significant uptick aligns with the increasing wallet counts, reinforcing the narrative that accumulation is providing a solid demand floor.

Historically, spikes in wallet growth among large and mid-sized holders have preceded notable price recoveries in XRP and other major cryptocurrencies. 

When deep-pocketed investors continue to accumulate, it often reflects growing conviction that the asset is undervalued relative to its long-term fundamentals.

Beyond short-term price movements, the expanding base of large holders could signal a structural shift in market sentiment, with investors increasingly viewing XRP as a strategic asset tied to real-world utility. 

The token’s connection to cross-border payment solutions and its alignment with ISO 20022 standards continue to make it a strong candidate for institutional adoption.

XRP Eyes Potential Rebound Amid Descending Channel FormationAccording to market analyst Degen Profit, XRP is currently trading at $2.37, showing signs of cautious consolidation within a descending channel. 

This technical pattern, often associated with corrective phases, has historically preceded substantial rallies for the cryptocurrency, sparking optimism among traders and investors.

Source: Degen ProfitThe key to XRP’s next move lies in its ability to maintain support within the critical $2.00–$2.20 zone. This range has historically acted as a strong foundation, providing a potential springboard for upward momentum. 

Should buyers successfully defend this level, XRP could be positioned for a rebound toward the next resistance at $2.72. A successful breach of this level could open the door to further gains, with $3.32 emerging as a significant target for mid-term bullish momentum.

Therefore, market sentiment has turned cautiously bullish as traders track XRP’s support levels, volume trends, and broader crypto movements. A rebound could gain momentum if Bitcoin and Ethereum recover, potentially sparking a wider altcoin rally.

ConclusionThe record surge in wallets holding more than 10,000 XRP signals a pivotal shift in market dynamics. Whales and mid-tier holders are steadily accumulating, reflecting strong confidence in XRP’s long-term potential and the attractiveness of current prices. 

As buying pressure grows and network participation expands, XRP’s foundation strengthens, setting the stage for a sustained, conviction-driven bullish phase led by the asset’s most influential stakeholders.

Notably, XRP sits at a pivotal $2.00–$2.20 support zone. Holding this level could spark a rebound toward $2.72, and potentially $3.32, as buyers step in within the descending channel, setting the stage for a bullish turnaround despite short-term volatility.